Skip to main content
Premium Trial:

Request an Annual Quote

Roche Dx Joins Spanish Personalized Med Study

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Roche Diagnostics said today that it is partnering with three Spanish entities, including two research institutes and the software developer Advance Biological Laboratories Therapy Edge Spain (ABL) to develop personalized antiviral treatment strategies for patients with chronic hepatitis C or B.

Roche and ABL's partners include the Vall d'Hebron Institute of Research (VIHR) and the Networking Biomedical Research Centre in Liver and Digestive Diseases (CIBERHED), which is comprised of eight research groups.

Roche said it will use its 454 sequencing systems and bioinformatics analysis, coupled with other genetic and molecular analysis techniques, to apply massively parallel sequencing in developing personalized antiviral treatments for chronic sufferers.

HCV infection causes chronic disease for nearly 180 million people, many of whom acquire the disease 15 to 25 years before they are diagnosed because the infection may remain asymptomatic until the advanced stages of the disease. That poses an expensive problem to health care systems, because in its advanced stages the disease requires a large amount of resources, including liver transplantation.

"The hepatitis C and B viruses exhibit great variability; a person infected with one of these viruses presents a complex population of variants comprising a structure known as 'quasi-species'," explained Juan Ignacio Esteban-Mur, a researcher at VIHR and a project coordinator at CIBERHED, in a statement. "The identification of these variants may be crucial for avoiding the selection of variants resistant to the new antiviral therapies."

Using 454 sequencing makes it possible to create a comprehensive profile of the complex viral populations that circulate in individuals in order to identify the quasi-species that are resistant to existing antiviral treatments, said Roche.

The Scan

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.

Study Points to Benefits of Local Consolidative Therapy, Targeted Treatments in Cancer Care

In JCO Precision Oncology, researchers report that local consolidative therapy combined with molecularly targeted treatments could improve survival for some lung cancer patients.

Genetic Variants That Lower LDL Cholesterol Linked to Reduced Heart Disease Risk

Rare variants in two genes that lower LDL cholesterol are also associated with a decreased risk of coronary heart disease, according to a new JAMA Cardiology study.

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.